Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 1011-1019. PMID: 21939942, DOI: 10.1016/j.jcin.2011.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionChronic DiseaseDrug-Eluting StentsEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansIsraelKaplan-Meier EstimateKidney DiseasesMaleMetalsMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsProspective StudiesProsthesis DesignRecombinant ProteinsRecurrenceRisk AssessmentRisk FactorsStentsStrokeThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionNet adverse cardiac eventsChronic kidney diseasePercutaneous coronary interventionTarget vessel revascularizationBare metal stentsDrug-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingBivalirudin monotherapyCoronary interventionKidney diseaseMyocardial infarctionRate of TVRIschemia-driven target vessel revascularizationNon-coronary artery bypassIIb/IIIa inhibitorsBenefit of bivalirudinDifferent antithrombotic strategiesAdverse cardiac eventsComposite of deathHigh rateEffect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis
Dangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möckel M, Caixeta A, Parise H, White H, Stone GW, Investigators H. Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis. Journal Of The American College Of Cardiology 2011, 57: 2309-2316. PMID: 21636031, DOI: 10.1016/j.jacc.2011.01.038.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionMajor bleedingMyocardial infarctionCardiac mortalityAcute ST-segment elevation myocardial infarctionST-segment elevation myocardial infarction (STEMI) patientsPrimary Percutaneous Coronary Intervention ResultsGlycoprotein IIb/IIIa inhibitorsPercutaneous Coronary Intervention ResultsElevation myocardial infarction patientsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBenefit of bivalirudinLate cardiac survivalProbable stent thrombosisPercutaneous coronary interventionTwo-year rateAcute myocardial infarctionMyocardial infarction patientsHORIZONS-AMISwitch patientsPrimary angioplastyControl patientsCoronary intervention